References

kpccz

Комплексные проблемы сердечно-сосудистых заболеваний

Complex Issues of Cardiovascular Diseases

2306-12782587-9537

Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”

10.17802/2306-1278-2020-9-2-6-16

kpccz-701

Research Article

Статьи

Коронавирусная инфекция - актуальная проблема XXI века

Coronavirus disease: a global problem of the 21st century

https://orcid.org/0000-0002-3023-6239

Баздырев

Е. Д.

Bazdyrev

E. D.

Баздырев Евгений Дмитриевич - доктор медицинских наук, заведующий лабораторией эпидемиологии сердечно-сосудистых заболеваний отдела оптимизации медицинской помощи при сердечно-сосудистых заболеваниях.

Сосновый бульвар, 6, Кемерово, 650002

Bazdyrev Evgeny D. - PhD, Head of the Laboratory for the Epidemiology of Cardiovascular Diseases, Cardiovascular Disease Medical Care Optimization Department

6, Sosonoviy Blvd., Kemerovo, 650002

edb624@mail.ru

Федеральное государственное бюджетное научное учреждение Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияFederal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”Russian Federation

2020

22062020

92616

2020

Баздырев Е.Д.

Bazdyrev E.D.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nii-kpssz.com/jour/article/view/701

В декабре 2019 г. в Китае зарегистрирована серия необъяснимых случаев пневмонии. Последующие исследования выявили новый штамм коронавируса - SARS-CoV-2, который является возбудителем острого инфекционного заболевания Coronavirus disease 2019 (COVID-19). За короткий период времени эпидемия новой коронавирусной инфекции переросла в пандемию, охватившую более 200 стран мира. Представленный обзор включает актуальные данные по этиологии, эпидемиологии, патогенезу, клиническим проявлениям, принципам диагностики и лечения коронавирусной инфекции нового типа, а также отражает представления о влиянии COVID-19 на сердечно-сосудистую систему.

A series of unexplained cases with pneumonia have been reported in China since December 2019. Subsequent studies have found a novel strain of coronavirus, SARS-CoV-2, as the causative agent of acute infectious disease that has been named as coronavirus disease 2019 (COVID-19). COVID-19 has outbroken as a global pandemic affecting over 200 countries. This review focuses on a novel coronovirus disease, reporting all available data on its etiology, epidemiology, pathogenesis, clinical manifestations, principles of diagnosis and treatment. In addition, the impact of COVID on the cardiovascular system is highlighted.

Коронавирусная инфекцияCOVID-19SARS-CoV-2ПандемияСердечнососудистые заболеванияОстрый респираторный дистресс-синдром

Coronavirus infectionCOVID-19SARS-CoV-2PandemicCardiovascular diseaseAcute respiratory distress syndrome

Публикация подготовлена в рамках сотрудничества с научно-образовательным центром мирового уровня «Кузбасс»

References1

Su S., Wong G., Shi W., Liu J., Lai A.C.K., Zhou J. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24: 490-502. doi: 10.1016/j.tim.2016.03.003.

Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-286. doi: 10.1007/s12098-020-03263-6.

Министерство здравоохранения Российской Федерации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Версия 4.0 (27.03.20). Режим доступа: https://urlid.ru/c30s (дата обращения 16.04.2020).

Ministerstvo zdravoohranenija Rossijskoj Federaciiю Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Vremennye metodicheskie rekomendacii. Versija 4.0 (27.03.20). [Ministry of Health of the Russian Federation. Temporary guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 4.0 (03/27/20). ]. Available at: https://urlid.ru/c30s (accessed 16.04.2020) (In Russian).

Chen Y, Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4):418-423. doi: 10.1002/jmv.25681.

Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181-192.

Chan K.S., Zheng J.P., Mok Y.W., Li Y.M., Liu Y.N., Chu C.M. et al. SARS: prognosis, outcome and sequelae. Respirology. 2003; 8(Suppl): 36-40. doi:10.1046/j.1440-1843.2003.00522.x

Badawi A., Ryoo S.G. Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis. J Public Health Res. 2016; 5(3): 733. doi: 10.4081/jphr.2016.733.

Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020. doi: 10.1007/s00392-020-01626-9.

Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020. doi: 10.1002/jmv.25722.

Стопкоронавирус.рф [интернет]. Режим доступа: https:// xn--80aesfpebagmfblc0a.xn--p1ai/# (дата обращения 16.04.2020).

Stopkoronavirus.rf: [Internet]. [Stopkoronavirus.rf: [Internet].]. Available at: https://xn--80aesfpebagmfblc0a.xn-p1ai/# (accessed 23.06.2013) (In Russian).

Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. doi: 10.1001/jama.2020.6019.

Han Y., Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective. J Med Virol. 2020. doi: 10.1002/jmv.25749.

Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective. J Med Virol. 2020. doi: 10.1002/jmv.25749.

Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020. doi: 10.1016/j.ijcard.2020.03.063.

Bai Y., Yao L., Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 21: 19-20.

Bai Y, Yao L., Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 21: 19-20.

Mizumoto K., Kagaya K., Zarebski A. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020; 25(10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.

Li Q., Guan X., Wu P., Zhou L., Tong Y, Ren R. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13): 1199-1207. doi:10.1056/NEJMoa2001316.

Li Q., Guan X., Wu P., Zhou L., Tong Y., Ren R. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13): 1199-1207. doi:10.1056/NEJMoa2001316.

Flahault A. Has China faced only a herald wave of SARS-CoV-2? Lancet. 2020; 395(10228): 947. doi: 10.1016/S0140-6736(20)30521-3 49.

Cobum B.J., Wagner B.G., Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009; 7(1): 30. doi: 10.1186/1741-7015-7-30.

Coburn B.J., Wagner B.G., Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009; 7(1): 30. doi:10.1186/1741-7015-7-30.

Menachery V.D., Yount B.L., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015; 21(12): 1508-1513. doi: 10.1038/nm.3985.

Menachery VD., Yount B.L., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015; 21(12): 1508-1513. doi: 10.1038/nm.3985.

Wan Y, Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020; 94(7): 1-9. doi: 10.1128/jvi.00127-20.

Jia H.P, Look D.C., Shi L., Hickey M., Pewe L., Netland J. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.

Jia H.P., Look D.C., Shi L., Hickey M., Pewe L., Netland J. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.

Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y, Prindle T., Fulton W.B., Wang S. et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018; 314(1): 17-31. doi: 10.1152/ajplung.00498.2016.

Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7.

Oudit G.Y, Kassiri Z., Jiang C., Liu P.P., Poutanen S. M., Penninger J.M. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009; 39(7): 618-625. doi: 10.1111/j.1365-2362.2009.02153.x.

Short K.R., Kroeze E.J.B.V., Fouchier R.A.M., Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014; 14(1): 57-69. doi: 10.1016/ S1473-3099(13)70286-X.

Mora R., Arold S., Marzan Y, Suki B., Ingenito E.P Determinants of surfactant function in acute lung injury and early recovery. Am J Physiol Lung Cell Mol Physiol. 2000; 279(2): 342-349. doi:10.1152/ajplung.2000.279.2.l342.

Mora R., Arold S., Marzan Y., Suki B., Ingenito E.P. Determinants of surfactant function in acute lung injury and early recovery. Am J Physiol Lung Cell Mol Physiol. 2000; 279(2): 342-349. doi:10.1152/ajplung.2000.279.2.l342.

Guan W.J., Ni Z.Y., Hu Y, Liang W.H., Ou C.Q., He J.X. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020. doi: 10.1056/NEJMoa2002032.

Guan W.J., Ni Z.Y, Hu Y, Liang W.H., Ou C.Q., He J.X. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020. doi: 10.1056/NEJMoa2002032.

Yang X., Yu Y, Xu J., Shu H., Xia J., Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 2600(20): 1-7. doi: https://doi.org/10.1016/S2213-2600(20)30079-5.

Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 2600(20): 1-7. doi: https://doi.org/10.1016/S2213-2600(20)30079-5.

Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Режим доступа: https://urlid.ru/c30r (дата обращения 18.04.2020).

Rukovodstvo po diagnostike i lecheniju boleznej sistemy krovoobrashhenija v kontekste pandemii COVID-19 [Guidelines for the diagnosis and treatment of circulatory system diseases in the context of the COVID-19 pandemic.]. Available at: https://urlid.ru/c30r (accessed 18.04.2020) (In Russian).

Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19: ключевые положения. Версия 1 от 07 апреля 2020 года. Методические рекомендации. Режим доступа: https://urlid.ru/c30q (дата обращения 18.04.2020).

Anesteziologo-reanimacionnoe obespechenie pacientov s novoj koronavirusnoj infekciej COVID-19: kljuchevye polozhenija. Versija 1 ot 07 aprelja 2020 goda. Metodicheskie rekomendacii [Anesthetics and resuscitation of patients with a new coronavirus infection COVID-19: key points. Version 1 of April 07, 2020. Guidelines]. Available at: https://urlid.ru/c30q (accessed 18.04.2020) (In Russian).

Li L.Q., Huang T., Wang Y.Q., Wang Z.P., Liang Y, Huang T.B. et al. COVID-19 patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.25757.

Huang C., Wang Y, Li X., Ren L., Zhao J., Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497506. doi: 10.1016/S0140-6736(20)30183-5.

Huang C., Wang Y, Li X., Ren L., Zhao J., Hu Y et al. Clinical features of patients infected with 2019 novel coronavirns in Wuhan, China. Lancet. 2020; 395(10223): 497506. doi: 10.1016/S0140-6736(20)30183-5.

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/jama.2020.1585.

Zhou F., Yu T., Du R., Fan G., Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020. doi: 10.1016/j.jacc.2020.03.031.

Li F., Li W., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742): 1864-1868. doi:10.1126/science.1116480.

Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8.

Xu Z., Shi L., Wang Y, Zhang J., Huang L., Zhang C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X.

Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020. doi: 10.1016/j.pcad.2020.03.001.

Zhou P, Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273. doi: 10.1038/s41586-020-2012-7.

Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273. doi: 10.1038/s41586-020-2012-7.

Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B,R,, Bax J.J., Morrow D.A. et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018; 72: 2231-2264. doi: 10.1016/j.jacc.2018.08.1038.

Buzon J., Roignot O., Lemoine S., Perez P, Kimmoun A., Levy B. et al. Takotsubo cardiomyopathy triggered by influenza A virus. Intern Med. 2015; 54(16): 2017-2019. doi: 10.2169/internalmedicine.54.3606.

Buzon J., Roignot O., Lemoine S., Perez P., Kimmoun A., Levy B. et al. Takotsubo cardiomyopathy triggered by influenza A virus. Intern Med. 2015; 54(16): 2017-2019. doi: 10.2169/internalmedicine.54.3606.

Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844-847. doi: 10.1111/jth.14768.

Fan B.E., Chong V.C.L., Chan S.S.W, Lim G.H., Lim K.G.E., Tan G.B. et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020. doi: 10.1002/ajh.25774.

Fan B.E., Chong V.C.L., Chan S.S.W., Lim G.H., Lim K.G.E., Tan G.B. et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020. doi: 10.1002/ajh.25774.

KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL, 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/la bel/2013/021251s046_021906s039lbl.pdf (accessed 13.04.2020)

DeCarolis D.D., Westanmo A.D., Chen Y.C., Boese A.L., Walquist M.A., Rector T.S. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother. 2016; 50(11): 909-917. doi: 10.1177/1060028016660325.

Frost C.E., Byon W., Song Y, Wang J., Schuster A.E., Boyd R.A. et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015; 79(5): 838-846. doi: 10.1111/bcp.12541.

Mueck W., Kubitza D., Becka M. Co-administration of rivaroxaban with drugs that share itselimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013; 76(3): 455-466. doi: 10.1111/bcp.12075.

Itkonen M.K., Tornio A., Lapatto-Reiniluoto O., Neuvonen M., Neuvonen PJ.,Niemi M. et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019; 105(1): 219-228. doi: 10.1002/cpt.1099.

Marsousi N., Daali Y., Fontana P, Reny J.L., Ancrenaz-Sirot V, Calmy A. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018; 57(10): 1347-1354. doi: 10.1007/s40262-018-0637-6.

Marsousi N., Daali Y, Fontana P., Reny J.L., Ancrenaz-Sirot V., Calmy A. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018; 57(10): 1347-1354. doi: 10.1007/s40262-018-0637-6.

Mulangu S., Dodd L.E., Davey R.T., Tshiani Mbaya O., Proschan M., Mukadi D. et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019; 381(24): 2293-2303. doi: 10.1056/NEJMoa1910993.

Wrapp D., Wang N., Corbett K.S. Goldsmith J.A.., Hsieh C.L., Abiona O. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260-1263. doi: 10.1126/science.abb2507.

Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016; 118(8): 1313-1326. doi:10.1161/CIRCRESAHA.116.307708.

Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016; 118(8): 1313-1326. doi:10.1161/CIRCRESAHA.116.307708.

The authors declare that there are no conflicts of interest present.